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To the editor: We do agree, with Dr Rengina Vorou [1], 
that knowledge gaps in the field of Zika virus (ZIKV) 
diagnostics urgently need to be addressed. Indeed, the 
use of molecular tests is limited by the short duration 
of viraemia; moreover, flavivirus serology is complex, 
due to extensive cross-reactivity between antibodies 
triggered by different flavivirus infections or vaccina-
tion. More generally, the reliance on the use of molecu-
lar and serological diagnostics to rule out or confirm 
infections requires careful consideration, as the expe-
rience of clinicians and diagnostic laboratories is lim-
ited by default for emerging diseases. At now, few 
available tests have been only, marginally, validated, 
and the laboratory community is in an urgent need for 
validation and evaluation of serology tests in the field.
However, we would like to make some clarifications on 
specific points in the letter: the most important one is 
that it is not accurate to state that we ‘concluded that 
the two patients were confirmed cases of Zika virus 
infection, on grounds of a positive PRNT’: indeed, we 
also, and most importantly, observed for both patients 
a sharp increase in the neutralising antibody titre 
between the first and second serum sample (from 1:10 
to ≥ 1:160), which is also considered in general a help-
ful diagnostic criterion (for example, see the European 
Centre for Disease Prevention and Control health pro-
fessional factsheet [2]).
The patients were tested retrospectively: however, 
we think that we could not detect viral nucleic acids 
in serum samples because the viraemic phase was 
already at its end at the time of samples collection 
(5 days after the onset of symptoms). We have sub-
sequently demonstrated through the use of positive 
plaque reduction neutralisation test (PRNT) that ZIKV 
specific neutralising antibodies were already present 
at that time (even if at a low titre). In our experience 
with dengue virus (DENV) and chikungunya, neutralis-
ing antibody positive serum samples are hardly poly-
merase chain reaction positive. The main limitation in 
our study is that urine samples were not collected.
We surely agree that PRNT should include any flavivirus 
that might be found in a given geographical area where 
a patient had previously been: however, although 
some cross-reactivity can still occur, virus neutralisa-
tion tests, particularly PRNTs, are considered the most 
specific serology for flaviviruses, and a ‘gold standard’ 
also for the evaluation of different serological tests. 
Indeed we obtained a ‘borderline’ result (inhibition of 
only 50% of plaques with a 1:10 serum dilution) with 
DENV PRNT in the second sample of both patients, so 
the criterion of a ratio of Zika to dengue virus PRNT 
titres less than four was met. However, it must be con-
sidered that this criterion can be useful for travellers, 
but much less for people residing in areas with circu-
lation of several different flaviviruses. As the National 
Reference Laboratory for Arboviruses, we have often 
observed PRNT ‘borderline’ (more rarely positive) 
results for closely related flaviviruses in cases of con-
firmed infection with a flavivirus (since we mainly con-
firm infections among travellers). However, we agree 
that a more accurate assessment of the degree of 
cross-reactivity in PRNT between different flaviviruses 
is needed.
Finally, there are several reasons for ruling out West 
Nile virus (WNV) infection in our patients: (i) symptoms 
like conjunctivitis (patient 1), and wrists and fingers 
oedema (patient 2) [3] are not typical of WNV infec-
tion [4]; (ii) no cases of WNV have been diagnosed 
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in Tuscany in the period 2008–2014 [5]; (iii) there is 
no evidence about recent active WNV circulation in 
Thailand [6], even if seropositivity for WNV was also 
noted in the past [7].
In conclusion, it should be stressed that, in our opin-
ion, at this stage, PRNT increasing titres are sufficiently 
specific to confirm Zika virus infection in presence 
of consistent clinical and epidemiological criteria. 
Of course, caution is needed in the interpretation of 
laboratory results in the absence of other criteria. It is 
important to consider the need for more specific tests 
and appropriate guidelines.
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